

Sep 02, 2021

Versatile Cell-Free Protein Synthesis Systems Based on Chinese Hamster Ovary Cells

✓ Book Chapter

Lena Thoring¹, Stefan Kubick¹¹Cell-free and Cell-based Bioproduction Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses Potsdam-Golm (IZI-BB), Potsdam-Golm, Germany

1 Works for me

Share

dx.doi.org/10.17504/protocols.io.bp3emqje

Springer Nature Books

satyavati Kharde

ABSTRACT

We present an alternative production platform for the synthesis of complex proteins. Apart from conventionally applied protein production using engineered mammalian cell lines, this protocol describes the preparation and principle of cell-free protein synthesis systems based on CHO cell lysates. The CHO cell-free system contains endogenous microsomes derived from the endoplasmic reticulum, which enables a direct integration of membrane proteins into a nature like milieu and the introduction of posttranslational modifications. Different steps of system development are described including the cultivation of CHO cells, cell harvesting and cell disruption to prepare translationally active CHO cell lysates. The requirements for DNA templates and the generation of linear DNA templates suitable for the CHO cell-free reaction is further depicted to underline the opportunity to produce different protein variants in a short period. This experimental setup provides a basis for high-throughput applications. The productivity of the CHO cell-free systems is further increased by using a non-canonical translation initiation due to the attachment of an internal ribosomal entry site of the Cricket paralysis virus (CRPV IRES) to the 5' UTR of the desired gene. In this way, a direct interaction of the IRES structure with the ribosome facilitates a translation factor independent initiation of translation. Cell-free reactions were performed in fast and efficient batch reactions leading to protein yields up to 40 µg/mL. The reaction format was further adjusted to a continuous exchange CHO cell-free reaction (CHO CECF) to prolong reaction time and thereby increase the productivity of the cell-free systems. Finally, protein yields up to 1 g/L were obtained. The CHO CECF system represents a sophisticated resource to address structural and functional aspects of difficult-to-express proteins in fundamental and applied research.

DOI

dx.doi.org/10.17504/protocols.io.bp3emqje

EXTERNAL LINK

https://link.springer.com/protocol/10.1007%2F978-1-4939-8730-6_19

PROTOCOL CITATION

Lena Thoring, Stefan Kubick 2021. Versatile Cell-Free Protein Synthesis Systems Based on Chinese Hamster Ovary Cells. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.bp3emqje>

MANUSCRIPT CITATION please remember to cite the following publication along with this protocol

Thoring L., Kubick S. (2018) Versatile Cell-Free Protein Synthesis Systems Based on Chinese Hamster Ovary Cells. In: Hacker D. (eds) Recombinant Protein Expression in Mammalian Cells. Methods in Molecular Biology, vol 1850. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8730-6_19

KEYWORDS

Cell-free protein synthesis, CHO cells , Continuous exchange cell-free systems , Difficult-to-express proteins , In vitro protein production, Internal ribosomal entry sites, Linear expression templates

LICENSE

————— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited





CREATED

Nov 24, 2020

LAST MODIFIED

Sep 02, 2021

OWNERSHIP HISTORY

Nov 24, 2020		Lenny Teytelman	protocols.io
Jul 05, 2021		Emma Ganley	protocols.io
Aug 24, 2021		Satyavati Kharde	
Aug 26, 2021		satyavati Kharde	

PROTOCOL INTEGER ID

44870

GUIDELINES

Introduction

Nowadays, protein synthesis plays a pivotal role in the pharmaceutical industry for the development and screening of novel therapeutical treatments and the production of drugs. There is an increasing demand of fast and efficient protein production platforms, while different cellular host organisms are conventionally used for the production of a target protein [1, 2]. One of the currently most relevant production hosts are Chinese hamster ovary (CHO) cells, a well-established, optimized, safe, and reliable production host for more than three decades [3, 4]. The development of appropriate cell hosts comprises a laborious and time-consuming developmental process and is limited for proteins, which show cytotoxic effects and folding issues during cellular overexpression. Membrane proteins and proteinogenic toxins belong to this class of so-called “difficult-to-express” proteins . Despite their challenging production process, these proteins harbor a high potential for pharmaceutical applications [5, 6]. In this context, novel protein productions platforms so called cell-free protein synthesis systems are continuously developed to provide a value-added technology. Cell-free protein synthesis system are typically based on cell lysates harboring the entire translational machinery in an active state [7, 8]. Until now, a broad range of cell-free protein synthesis systems has been developed differing in their cellular origin and their performance [9]. In general, the systems can be subdivided into prokaryotic and eukaryotic cell-free systems, while the selection of the production platform depends on the complexity of the desired target protein [10]. Eukaryotic cell-free protein synthesis systems are generally used for the production of pharmaceutically relevant and complex mammalian proteins. Special eukaryotic cell-free systems contain endogenous microsomes derived from the endoplasmic reticulum due to a mild cell disruption procedure during lysate preparation. Microsomes enable an integration of membrane embedded and associated proteins into a nature-like milieu, a cotranslational translocation of proteins as reported in cellular protein expression processes and they harbor a fully ER based set of enzymes for folding and posttranslational modifications including relevant glycosyltransferases for attachment of glycan moieties, chaperones and essential molecules for the introduction of disulfide bridges [11-14]. In order to combine a mammalian host cell often used for the production of versatile, mammalian proteins and a cell-free platform, we have recently developed novel systems based on the prominent industrial protein production host CHO cells [15, 16]. This platform provides a user-friendly system completing the classical industrial protein production pipeline. The fast, efficient, and high-throughput compatible protein synthesis tool promotes DNA template pre-evaluation as well as production of difficult-to-express proteins [17]. To realize these demands a coupled

transcription/translation system is developed containing endogenous microsomal structures for posttranslational modifications and cotranslational membrane protein integration. To address individual applications, the system is adapted to different reaction modes including a fast batch based [18] and a highly productive continuous exchange cell-free system (CECF) leading to protein yields up to 1 g/L [19]. A concept is proposed for the application of linear DNA templates apart from circular DNA to expand the platform by a fast and cloning-free DNA template generation process.

This chapter includes an overview covering the entire process pipeline for the development of CHO cell-free systems. In this protocol, we present the preparation of cell-free systems containing the cultivation of CHO cells, the preparation of translationally active lysate, the generation of linear expression templates and finally the cell-free production of proteins using batch and CECF formatted systems.

Notes

1. Serum-free and chemically defined media are used for the cultivation of CHO cells prior to their utilization in lysate production procedure. This enables low batch-to-batch variation and therefore a high reproducibility in the cultivation step for the subsequent production of translationally active CHO cell lysates.
2. Aeration and stirring conditions in the bioreactor for the production of CHO cell biomass are adapted to obtain a stress reduced cultivation procedure. Induction of cell stress response can lead to inactivation of translation factors due to kinase dependent phosphorylation reactions and activation of the cell death response including the overexpression of caspases, a class of cysteinyl-aspartate specific proteases that reportedly cleave translation factors thereby reducing the productivity of the protein translation machinery.
3. All cultivation relevant parameters were directly implemented into MFCS SCADA bioprocess software. Thereby growth relevant values can be directly monitored to estimate the point of harvest of the biomass for lysate production. CHO cells harvested in the late log phase resulted in the highest translational activity of produced cell lysates.
4. Cultured CHO cells were microscopically analyzed during cell cultivation, after harvesting and washing procedures, and after cell disruption to verify cell stress response by the morphology of cells and the degree of cell disruption.
5. The regulatory sequence donor vector contains the 5' regulatory sequences required for transcription and translation reaction including the Cricket Paralysis Virus IGR IRES and the T7 RNA polymerase promoter.
6. Regulatory overlap sequences consist of 10–15 base pairs complementary to the 3' end of the CRPV IGR IRES for the N-terminal gene specific primer and a 10 base pair overlap to the T7 terminator for the C-terminal gene specific primer.
7. The HotStar HiFidelity DNA polymerase is a hot-start proofreading enzyme, which enables the amplification of PCR -products with a minimized rate of mutation incorporation. Factor SB in the PCR buffer prevents degradation of primers and DNA-template during PCR.
8. The EasyXpress pIX3.0 cell-free expression vector backbone contains regulatory N- and C-terminal sequences for the application in various prokaryotic and eukaryotic cell-free protein synthesis systems.
9. Repeated freeze/thaw cycle (up to 5 times) does not affect the quality of the translation and energy buffers. Ready prepared CHO lysate shows no loss of activity by three repeated freeze/thaw cycles.
10. The caspase inhibitor is initially dissolved in DMSO to increase its stability during freezing and storage. For the application to the cell-free synthesis reaction, the caspase inhibitor is further diluted in water.
11. The degree of cell disruption is monitored by microscopic imaging. If a high degree of intact cells is present after initial disruption, a repetition of the cell disruption step is performed.
12. If intact cells are available after cell disruption, these cells will be removed by the centrifugation step due to their sedimentation coefficient.
13. The ready prepared raw lysate can be stored for more than 5 years at -80°C without significant loss of activity.
14. 1 μL of the PCR sample is diluted in 2 μL of sample buffer and 9 μL of Millipore water and loaded onto a 1% agarose gel. The agarose gel is run for 60 min at 100 V for the separation of DNA samples. Detection of DNA was accomplished using DNA intercalating dye DNA safe stain and an UV detection unit.
15. For application of a linear expression template to a cell-free reaction no further purification of the PCR product is required.
16. The preparation of plasmid DNA is performed according to the manufacture's protocol.
17. Thawing of cell-free components on ice enables a mild and slow thaw procedure which prevents the degradation and inactivation of enzymatic and translation related components.
18. Apart from the standardized pIX3.0 cell-free expression vector, various vector backbones can be applied to the CHO cell-free synthesis reaction. Requirements for the application to the CHO cell-free reaction are the

presence of a T7 RNA polymerase promotor/terminator and an IRES sequence. Optimal concentrations of the plasmid depend on the type of plasmid applied. It is mandatory to evaluate each individual vector backbone to obtain increased protein yields.

19. Supplementation of PEG and Ficoll induce molecular crowding effects, which lead to an increased activity of T7 RNA polymerase.
20. Autoradiographs are prepared after separation of protein samples on SDS-PAGE. The SDS-PAGE is dried on a unigel dryer and exposed on a phosphor-screen for 3 days. The autoradiography is completed using a multimode imager (Typhoon Trio Plus, GE-Healthcare).
21. The evaluation of fluorescent proteins was performed using a multimode imager. For this, 5 µL of cell-free produced protein sample is diluted with 20 µL PBS and directly applied to a µ-ibidi slide. The ibidi slide can be placed in the multimode imager for fluorescence imaging.
22. Sodium azide is a supplement for the CHO CECF reaction to prevent microbial contamination.
23. The application of linear expression templates to a cell-free system generally leads to decreased protein yields compared to a circular DNA expression template. This fact is due to the decreased stability of linear DNA templates in cell-free systems.

Acknowledgments

This work was supported by Fraunhofer High Performance Center for Functional Integration in Materials, the European Regional Development Fund (EFRE), and the German Ministry of Education and Research (BMBF, No. 031B0078A).

References

1. Bandaranayake AD, Almo SC (2013) Recent advances in mammalian protein production. *FEBS Lett* 588(2):253–260. <https://doi.org/10.1016/j.febslet.2013.11.035> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
2. Merlin M, Gecchele E, Capaldi S, Pezzotti M, Avesani L (2014) Comparative evaluation of recombinant protein production in different biofactories: the green perspective. *Biomed Res Int* 2014:14. <https://doi.org/10.1155/2014/136419> [CrossRef](#) [Google Scholar](#)
3. Kim JY, Kim Y-G, Lee GM (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. *Appl Microbiol Biotechnol* 93(3):917–930. <https://doi.org/10.1007/s00253-011-3758-5> [CrossRef](#) [PubMed](#) [Google Scholar](#)
4. Lai T, Yang Y, Ng SK (2013) Advances in mammalian cell line development technologies for recombinant protein production. *Pharmaceuticals* 6(5):579–603. <https://doi.org/10.3390/ph6050579> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
5. Harvey AL (2014) Toxins and drug discovery. *Toxicon* 92:193–200. <https://doi.org/10.1016/j.toxicon.2014.10.020> [CrossRef](#) [PubMed](#) [Google Scholar](#)
6. Yin H, Flynn AD (2016) Drugging membrane protein interactions. *Annu Rev Biomed Eng* 18:51–76. <https://doi.org/10.1146/annurev-bioeng-092115-025322> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
7. Carlson ED, Gan R, Hodgman CE, Jewett MC (2012) Cell-free protein synthesis: applications come of age. *Biotechnol Adv* 30(5):1185–1194. <https://doi.org/10.1016/j.biotechadv.2011.09.016> [CrossRef](#) [PubMed](#) [Google Scholar](#)
8. Chong S (2014) Overview of cell-free protein synthesis: historic landmarks, commercial systems, and expanding applications. *Curr Prot Mol Biol* 108:16.30.1–16.30.11. <https://doi.org/10.1002/0471142727.mb1630s108> [CrossRef](#) [Google Scholar](#)
9. Lu Y (2017) Cell-free synthetic biology: engineering in an open world. *Synth Syst Biotechnol* 2(1):23–27. <https://doi.org/10.1016/j.synbio.2017.02.003> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
10. Zemella A, Thoring L, Hoffmeister C, Kubick S (2015) Cell-free protein synthesis: pros and cons of prokaryotic and eukaryotic systems. *Chembiochem* 16(17):2420–2431. <https://doi.org/10.1002/cbic.201500340> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
11. Brodel AK, Wustenhagen DA, Kubick S (2015) Cell-free protein synthesis systems derived from cultured mammalian cells. *Methods Mol Biol* 1261:129–140. https://doi.org/10.1007/978-1-4939-2230-7_7 [CrossRef](#) [PubMed](#) [Google Scholar](#)
12. Buntru M, Vogel S, Stoff K, Spiegel H, Schillberg S (2015) A versatile coupled cell-free transcription-translation system based on tobacco BY-2 cell lysates. *Biotechnol Bioeng* 112(5):867–878. <https://doi.org/10.1002/bit.25502> [CrossRef](#) [PubMed](#) [Google Scholar](#)
13. Hodgman CE, Jewett MC (2013) Optimized extract preparation methods and reaction conditions for improved

- yeast cell-free protein synthesis. *Biotechnol Bioeng* 110(10):2643–2654. <https://doi.org/10.1002/bit.24942> [CrossRef](#) [PubMed](#) [Google Scholar](#)
14. Kubick S, Schacherl J, Fleischer-Notter H, Royall E, Roberts LO, Stiege W (2003) In vitro translation in an insect-based cell-free system. In: Swartz JR (ed) *Cell-free protein expression*. Springer, Berlin, Heidelberg, pp 209–217 [CrossRef](#) [Google Scholar](#)
 15. Brodel AK, Sonnabend A, Kubick S (2014) Cell-free protein expression based on extracts from CHO cells. *Biotechnol Bioeng* 111(1):25–36. <https://doi.org/10.1002/bit.25013> [CrossRef](#) [PubMed](#) [Google Scholar](#)
 16. Brodel AK, Sonnabend A, Roberts LO, Stech M, Wüstenhagen DA, Kubick S (2013) IRES-mediated translation of membrane proteins and glycoproteins in eukaryotic cell-free systems. *PLoS One* 8(12):e82234. <https://doi.org/10.1371/journal.pone.0082234> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
 17. Ogonah OW, Polizzi KM, Bracewell DG (2017) Cell free protein synthesis: a viable option for stratified medicines manufacturing. *Curr Opin Chem Eng* 18:77–83. <https://doi.org/10.1016/j.coche.2017.10.003> [CrossRef](#) [Google Scholar](#)
 18. Thoring L, Wüstenhagen DA, Borowiak M, Stech M, Sonnabend A, Kubick S (2016) Cell-free systems based on CHO cell lysates: optimization strategies, synthesis of "difficult-to-express" proteins and future perspectives. *PLoS One* 11(9):e0163670. <https://doi.org/10.1371/journal.pone.0163670> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
 19. Thoring L, Dondapati SK, Stech M, Wüstenhagen DA, Kubick S (2017) High-yield production of "difficult-to-express" proteins in a continuous exchange cell-free system based on CHO cell lysates. *Sci Rep* 7(1):11710. <https://doi.org/10.1038/s41598-017-12188-8> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)
 20. Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, Gold DS, Heinsohn HG, Murray CJ (2011) Microscale to manufacturing scale-up of cell-free cytokine production—a new approach for shortening protein production development timelines. *Biotechnol Bioeng* 108(7):1570–1578. <https://doi.org/10.1002/bit.23103> [CrossRef](#) [PubMed](#) [PubMedCentral](#) [Google Scholar](#)

MATERIALS TEXT

2.1 Cell Cultivation

1. CHO -K1 cells are purchased from a cell bank (DSZM, Germany) and adapted to serum-free suspension cultivation (*see Note 1*).
2. For the initial cultivation of the CHO cells, shake flasks (Corning) of different sizes (from 125 mL up to 1 L) are used.
3. Cell density and viability are evaluated using a Thoma cell counting chamber and trypan blue staining.
4. CO₂-Incubator Multitron (Infors) for cultivation of CHO cells in shake flasks.
5. Conventional stirred tank bioreactors in a scale of 5 L (Biostat B-DCUII, Sartorius Stedim Biotech GmbH) up to 30 L (Biostat D-DCU) including an aeration basket for bubble-free aeration (*see Note 2*). An internal spin filter is implemented to enable perfusion based fermentation.
6. Diverse sensor units for online monitoring of cell cultivation process: pH probe, pO₂ probe, level sensor (Hamilton and Sartorius Stedim Biotech GmbH).
7. MFCS SCADA software (bioprocess control) (Sartorius Stedim Biotech GmbH) (*see Note 3*).
8. 1 M Sodium carbonate solution (Sigma-Aldrich) for the adjustment of pH during fermentation.
9. Chemically defined PowerCHO2CD medium (Lonza) supplemented with 6 mM stabilized glutamine (Sigma-Aldrich).
10. Wash and resuspension buffer: 40 mM HEPES-KOH (pH 7.5), 100 mM NaOAc and 4 mM DTT. Store at 4 °C.
11. Light microscope BX40 and Cell D Software (Olympus) (*see Note 4*).

2.2 Cell Disruption and CHO Lysate Preparation

1. Wash buffer (*see* Section 2.1 "Cell Cultivation" above, **item 10**).
2. Syringe with 20-gauge needle or high-pressure homogenizer.
3. Nanodrop 2000c (Thermo Scientific).
4. Sephadex G-25 columns (NAP 25 or Äkta Prime (GE-Healthcare)). Stored at 4 °C.
5. S7 Nuclease (Roche) (200 U/μL). Stored at –20 °C.
6. 80 mM CaCl₂ and 80 mM EGTA dissolved in water and stored at 4 °C.
7. Creatine kinase dissolved in water (1 mg/mL) and stored at –20 °C.
8. Baker's yeast tRNA (17.5 μg/mL) dissolved in water and stored at –80 °C.
9. High speed centrifuge (Beckmann Coulter) for cell harvesting.

2.3 Generation of Suitable Linear and Circular DNA Expression Templates

1. Sequence of the gene of interest (GOI).
2. Regulatory sequence donor vector containing the 5'-terminal regulatory sequences necessary for CHO cell-free synthesis (*see Note 5*).

3. T7 RNA polymerase promotor (5' UTR) and terminator (3' UTR) sequence.
4. Sequence of the Cricket paralysis virus (CRPV) IGR IRES (Genbank accession no. AF218039, nucleotides 6025–6216).
5. Gene specific primer pairs for the amplification of the gene of interest and the attachment of regulatory overlap sequences (*see* **Note 6**).
6. Regulatory adapter primers (Reg-F, Reg-R, CRPV-R) for the introduction of required regulatory sequences.
7. PCR thermocycler (Bio-Rad).
8. HotStar HiFidelity DNA Polymerase and appropriate buffer including dNTPs (Qiagen) (*see* **Note 7**).
9. Perfect Blue Gel System and universal Agarose (Peqlab).
10. Rotiphorese 10× TBE-buffer (Carl Roth).
11. DNA Stain Clear G (SERVA).
12. 2-log DNA ladder 0.1–10 kb (NEB).
13. EasyXpress pIX3.0 cell-free expression vector backbone for direct cloning of generated PCR products into a circular plasmid applicable for cell-free protein synthesis (Biothecrabbit) (*see* **Note 8**).
14. Plasmids including the gene of interest suitable for cell-free protein synthesis (Geneart Gene Synthesis service (Thermo Fisher Scientific) or BioCat).
15. Electroporation device and cuvettes (Biorad).
16. E.coli JM109 strain (New England Biolabs).
17. LB media (Carl Roth).
18. Antibiotics (Sigma-Aldrich).
19. PureLink HiPure Plasmid Prep Kit (Thermo Fisher Scientific).
20. Restriction enzymes for the verification of target gene integration into a plasmid.
21. Nanodrop C for the estimation of plasmid DNA concentration.
22. Primers for DNA sequencing: M13-F5' GTA AAA CGA CGG CCA GTG3', M13-R 5' CAG GAA ACA GCT ATG AC 3'.

2.4 Batch Formatted CHO Cell-Free Synthesis of Proteins

1. 1.5 mL reaction tubes.
2. Thermomixer comfort (Eppendorf).
3. Previously prepared CHO lysate. Store at –80 °C.
4. Translation buffer (10×): 300 mM HEPES-KOH (pH 7.6), 2250 mM KOAc, 2.5 mM spermidine, 25 mM of DTT, 1 mM of each of the 20 canonical amino acids (Merck) and 39 mM Mg(OAc)₂. Store at –80 °C (*see* **Note 9**).
5. Energy buffer (5×): 100 mM creatine phosphate, 8.75 mM ATP, 1.5 mM CTP, 1.5 mM UTP, 1.5 mM GTP (Roche), and 0.5 mM m⁷G(ppp)G cap analogue. Store at –80 °C (*see* **Note 9**).
6. T7 RNA polymerase (3 U/μL) for performing the transcription reaction in the transcription-translation coupled system. Store at –20 °C.
7. ¹⁴C Leucine (PerkinElmer) (final concentration of 66.67 dpm/pmol) for radiolabeling of proteins. Store at –20 °C.
8. Linear expression template or plasmid DNA containing the GOI. Store at –20 °C.

2.5 Continuous Exchange Cell-Free Synthesis Based on CHO Lysate

1. Two chamber dialysis device (Membrane cut-off: 10 kDa, 50 μL reaction chamber, 1000 μL feeding chamber) (Biotech Rabbit).
2. Thermomixer C (Eppendorf).
3. Translationally active CHO lysate. Store at –80 °C (*see* **Note 9**).
4. Translation buffer (10×) (*see* Section 2.4 "Batch Formatted CHO Cell-Free Synthesis of Proteins" above, **item 4**).
5. Energy buffer: Energy buffer (5×) containing the following components: 92.5 mM creatine phosphate, 8.75 mM ATP, 1.5 mM CTP, 1.5 mM UTP, 1.5 mM GTP (Roche). Store at –20 °C.
6. T7 RNA polymerase (1 U/μL) for performing the transcription reaction in the transcription-translation coupled system. Store at –20 °C.
7. Caspase inhibitor AC-DEVD CMK (Santa Cruz Biotechnology) diluted in water (*see* **Note 10**).
8. 2500 mM Mg(OAc)₂ in water. Store at –20 °C.
9. ¹⁴C Leucine (PerkinElmer) (final concentration of 66.67 dpm/pmol) for radiolabeling of proteins. Store at –20 °C.
10. Linear expression template or plasmid DNA containing the GOI. Store at –20 °C.

SAFETY WARNINGS

Please refer to the Safety Data Sheets (SDS) for health and environmental hazards.

3.1 Biomass Production

- 1 Initially culture CHO -K1 cells in shake flask starting with a density between 0.5 and 0.7 × 10⁶ cells/mL. Cultivation conditions are set to a temperature of **37 °C**, a CO₂ concentration of 5% and a shaking speed of 100 RPM.

2 For biomass production, the stirred tank bioreactor is inoculated with CHO-K1 cells precultured in shake flasks at an initial density of around 1.0×10^6 cells/mL.

3 The fermentation process can be performed in repeated batch or perfusion mode:

3.1 The repeated batch process includes a cell growth phase of approximately 2 days to obtain cell densities between 4 and 5×10^6 cells/mL grown in the exponential growth phase, which is followed by the cell harvest. A defined volume of cell suspension remains in the cultivation vessel to start a second cycle of batch cultivation. The repeated batch is performed for 3 cycles.

3.2 To increase the produced biomass, a perfusion fermentation process can be applied to the CHO cell lysate preparation protocol. For this, CHO cells are inoculated at a density of 1×10^6 cells/mL, perform a batch based process until a density between 3 – 4×10^6 cells/mL is reached and start perfusion mode using a perfusion rate of 0.5 RV/day (RV: reactor volume).

Exponentially grown CHO cells can be harvested at different cell densities during the perfusion process without the loss of translational activity of CHO cell lysate (Fig. 1).




Fig. 1
Application of continuous fermentation for CHO biomass production used for the preparation of CHO cell-lysates. CHO cells are cultured in a 5 L cultivation vessel connected to a Biostat B-DCU II regulation unit (Sartorius Stedim). Different regulation and monitoring systems are connected to the fermentation vessel including a level probe, pH sensor, and pO₂ sensor as illustrated in (a). Continuous cultivation is realized by the introduction of a spin filter for cell retention and implementation of several pumps to enable feeding with fresh culture medium and removal of inhibitory byproducts. The perfusion process is started at a cell density of around 4×10^6 cells/mL and a perfusion rate of 0.5 reactor volumes/day. Fermentation parameters are monitored using MFCS SCADA software (b). CHO cell densities and viabilities are estimated by a Thoma counting chamber and trypan blue staining. Cells are harvested at different cell densities to evaluate the possibility to use high cell-density cultures for production of translationally active CHO cell lysate. Times of harvest are indicated by black arrows. (c) shows the quality of the produced CHO cell lysate analyzed using batch formatted cell-free protein synthesis. Quality control was based on the cell-free protein synthesis of model protein luciferase (DNA template: pIX3.0-CRPV-Luc) and analysis of luciferase activity using a standard luciferase assay (Promega) and luminescence detection using a multimode microplate reader (Berthold). Protein yield was calculated by application of a previously prepared calibration curve. Error bars indicate one standard deviation ($n = 6$, harvests 1 and 4; $n = 12$, harvests 2 and 3). No significant differences in luciferase activity were detected using CHO cell lysates harvested at different cell densities showing the possibility of using high cell-density cultures for lysate production


4 



Exponentially grown CHO cells are harvested by centrifugation using a fixed angle rotor or a continuous flow rotor depending on the volume of cell suspension.


5 

After harvesting cells are washed with HEPES based wash buffer (*see* Materials section 2.1 "Cell Cultivation", **item 10**) to remove culture medium components.

6 Before cell disruption, suspend CHO cells in wash buffer to obtain a final density of approximately 1.0×10^8 cells/mL.7 For preparation of translationally active CHO lysate, which contains endogenous microsomes, a mild disruption procedure is required. Therefore, disrupt CHO cells mechanically by passing the suspended cell pellet through a 20-gauge needle or disruption using high-pressure homogenization (*see* **Note 11**).8 

A raw CHO lysate is further prepared by differential centrifugation at  **10000 x g, 4°C, 00:10:00**. This step is required for the removal of cell debris, cell nuclei and cellular organelles (*see* **Note 12**). Raw lysate can be flash frozen using liquid nitrogen and stored at -80°C prior to further recondition steps.


9 Raw lysate is applied to a preequilibrated Sephadex G-25 column and elute using wash buffer (*see* Materials section 2.1 "Cell Cultivation", **item 10**). Collect fractions of 1 mL and quantify RNA concentration by absorbance estimation using the NanoDrop 2000C. Pool fractions displaying an absorbance above 1 at 260 nm.10 Pooled fractions are treated with micrococcal S7 nuclease (10 U/mL) to digest and remove endogenous mRNA. The ^{2m}S7 nuclease has a calcium dependent digestion activity, therefore add 1 mM of CaCl_2 to the enzyme containing eluate and incubate for  **00:02:00** at  **Room temperature**.11 The enzymatic reaction is inactivated using the Ca^{2+} chelating reagent EGTA (6.7 mM final concentration).12 The energy regenerating enzyme creatine kinase (100 $\mu\text{g/mL}$ final concentration) is added to the lysate to enable the regeneration of ATP using creatine phosphate as a phosphate donor.13 

The final translationally active CHO lysate is flash frozen and stored at  **-80°C** (*see* **Note 13**).

3.3 Generation of Linear Expression Templates

14

The application of linear DNA templates to the cell-free reaction offers a fast, flexible and cost-efficient approach to produce diverse proteins with different modifications, signal peptides and protein tags. To obtain a linear DNA template suitable for CHO cell-free protein synthesis, a two-step PCR procedure needs to be performed to add the required regulatory sequences to a target gene. A general overview of the procedure is illustrated in Fig. 2.

- 15 The gene of interest is amplified using gene specific adapter primers harboring an overlap to the 5'- and 3'- regulatory sequences.
- 16 The 5'- regulatory sequences, which contains a stem loop for stabilization, the T7 RNA promotor and the CRPV IGR IRES, are amplified using a regulatory sequence donor vector, Reg-F and CRPV-R primer.
- 17 Subsequently, verify the presence of both PCR products on agarose gel prior to their fusion and the generation of the final linear expression template (*see* **Note 14**).
- 18 Fusion PCR is performed by application of both previously generated DNA fragments (gene fragment and 5'- regulatory fragment) in an equimolar amount to the reaction and supplementation of regulatory primers (Reg-F and Reg-R). A high-fidelity DNA dependent polymerase is used for DNA amplification to enable a high correctness of produced DNA sequence by low misincorporation rates and proof reading activities.
- 19 Analyze the produced linear PCR fragment on an agarose gel prior to the application to the cell-free reaction (*see* **Note 15**).
- 20  Different signal peptides, purification tags and fluorescence tags can be integrated into the DNA sequences by the previously described procedure. For this, overlap sequences and regulatory primer pairs need be adapted to the individual requirements.





Fig. 2 Schematic overview of linear expression template generation for CHO cell-free synthesis. A two-step procedure is used for the generation of cell-free compatible linear DNA templates. The first step includes the amplification of the gene of interest (GOI) using gene-specific primer pairs. This step includes the fusion of overlap sequences to 5'- and 3'- regulatory sequences. Additionally, the 5'- regulatory sequence including stem loops for stabilization, the T7 RNA polymerase promoter for initiation of transcription and the Cricket paralysis virus IGR IRES for translation initiation factor independent translation initiation, is amplified using a regulatory donor vector and the Reg-F and CRPV-R primers. Both PCR products are fused during the second step of PCR using the Reg-F primer, and 3'-terminal regulatory sequences are added to the GOI by application of the Reg-R primer. After the second step, a ready-to-use linear DNA template for the CHO cell-free reaction is prepared



3.4 Preparation of Circular Plasmid Templates

21 Transformation of the desired plasmid template into *E. coli* JM109 cells is performed by electroporation using a 1 mM cuvette and a Biorad electroporation system.

22 

Transformed cells are plated on agar-antibiotic plats for *E. coli* clone growth. Transformed *E. coli* cell stocks are stored in glycerol at  **-80 °C**.

23 

E. coli cell clone is picked and inoculated into a shake flask containing LB medium and the appropriate antibiotics and cultured  **Overnight** at  **37 °C 120 RPM**.

24 Amplified plasmid DNA is isolated from *E. coli* overnight culture using the PureLink HiPure Plasmid Prep Kit (**see Note 16**).

25 Concentration of isolated plasmid DNA was analyzed at an absorbance of 260 nm using the Nanodrop 2000 C. A 260/280 purity value around 1.8 is required for further applicability of the plasmid DNA to a cell-free protein synthesis reaction.

26 Gene integration is evaluated by treatment of isolated plasmid DNA with restriction enzymes and separation of obtained DNA fragments by agarose gel electrophoresis. DNA fragment size is estimated using Clone Manager Software.

27 The DNA sequence is further verified by gene sequencing using M13-F and M13-R primers.

3.5 Cell-Free Synthesis in a Batch-Formatted Reaction

3h

28 All required components for cell-free protein synthesis are thawed **On ice** prior to their use in the reaction (see **Note 17**).

29 Batch formatted CHO cell-free reactions are performed in Eppendorf tubes containing reaction volumes from 20 μ L up to 500 μ L. Reports of prokaryotic cell-free systems show the possibility for process scale up to 100 L reaction volume [20].

30 To prevent RNase contamination, pipette CHO cell-free reactions using filter tips.

31 The preparation of the cell-free CHO batch reaction is performed **On ice**. The general principle of the CHO lysate based cell-free protein synthesis is illustrated in Fig. 3a.

32 The transcription/translation coupled CHO cell-free batch reaction is composed of 40% CHO cell lysate, 10% translation buffer and 20% energy buffer.

33 Typically, 20 nM of plasmid DNA is added to the reaction but the optimal concentration depends on the applied vector backbone (see **Note 18**).

34 To enable transcription of mRNA, supplement 1 U/ μ L T7 RNA polymerase to the CHO cell-free reaction.

35 For further analysis of produced proteins, 14 C leucine (specific radioactivity: 66.67 dpm/pmol) is added to the reaction and cotranslationally incorporated into the synthesized proteins.

36 Reaction volume is adjusted by supplementation with Millipore water to the final volume.

37 Optimization experiments included a further increase of T7 RNA polymerase to 3 U/ μ L and the supplementation of molecular crowding reagents (PEG, Ficoll) (see **Note 19**).

38 All components were pipetted directly to the reaction while adjusting the volume by adding ddH₂O. Standard conditions present in a batch-formatted CHO cell-free reaction are summarized in Table 1.

Table 1

List of standard reaction conditions present in a batch-formatted CHO cell-free system: optimized conditions are

indicated in bold letters

A	B
Component/Parameter	CHO batch reaction conditions
Cell lysate	40% (vol/vol)
HEPES KOH, pH 7.6	30 mM
KoAc	150 mM
Mg(OAc) ₂	3.9 mM
ATP	1.75 mM
CTP,GTP,UTP	0.3 mM
m7G(ppp)G cap (cap I)	0.1 mM
Amino acids	100 µM
¹⁴ C Leucine	66.67 dpm/pmol
Plasmid concentration	20 nM
T7 RNA polymerase	1 U/µL (3 U/µL)
DTT	2.5 mM
PEG 1500	2%
Temperature	30 °C
Agitation	600 RPM
Reaction time	3 h

39

3h

Ready prepared cell-free translation mixture is incubated for **03:00:00** at **30 °C 600 RPM** using a thermomixer.

40

The CHO cell-free translation mixture can be directly used for further analysis of the produced protein. Cell-free synthesized proteins can be applied to various assays. Radio labeled proteins can be quantified using TCA precipitation followed by scintillation measurement.

41 Molecular weight and protein modifications can be analyzed by separation of acetone-precipitated proteins on SDS-PAGE followed by autoradiography.

42 Figure 3 shows exemplary CHO cell-free synthesis of membrane protein and ion channel KvAP. Functional membrane^{15m} proteins are integrated into the ER derived microsomes of CHO lysate. Microsomes can be separated by centrifugation (**16000 x g, 4°C, 00:15:00**). Proteins integrated into the microsomes can be enriched by a repetitive addressing procedure. For this, a batch based cell-free reaction is initially performed followed by the separation of microsomal fraction. The separated microsomes are dissolved in a freshly prepared cell-free reaction depleted from microsomes, which enables the enrichment of translocated proteins into microsomes. This procedure is performed for three repetitive cycles. A schematic overview is illustrated in Fig. 3b. The produced membrane protein KvAP shows the formation of monomeric and multimeric structures in the autoradiograph (Fig. 3c). An increase in produced membrane protein is detected in the microsomal fraction (Fig. 3d) (*see***Note 20**).




Fig. 3 Batch formatted cell-free synthesis based on CHO cell lysates. **(a)** Schematic overview of CHO cell-free protein synthesis using batch mode. The batch formatted cell-free protein synthesis system consists of the CHO cell lysate, T7 RNA polymerase, nucleotides, a DNA template containing the GOI, and supplementation components. The exact protocol is described in Section 3.5 'Cell-Free Synthesis in a Batch-Formatted Reaction'. The translation mixture can be separated into ER derived microsomes and a supernatant 1 fraction by centrifugation ($16,000 \times g$, 4°C , 15 min). The microsomal fraction contains proteins, which are cotranslationally translocated into the microsomes by signal peptide SRP-complex interaction. The microsomes enable direct integration of membrane proteins into a natural milieu having ER based posttranslational modifications. **(b)** describes a repetitive translation of proteins into the microsomes for enrichment of secretory and membrane embedded proteins. For this, a general cell-free reaction is performed. After finishing the reaction, microsomes are separated by centrifugation and supernatant 1 is removed. Previously addressed microsomes are supplemented with a freshly prepared translation mixture depleted of microsomes. An example for an enrichment of a membrane protein is depicted in **(c)** and **(d)**. For this, the ion channel KvAP is synthesized into the microsomes using three repetitive protein production cycles in the batch formatted CHO cell-free system. **(c)** shows an autoradiograph of translations mixture (TM), supernatant 1 (SN1), and microsomal fraction (MF) of the different repetitive cycles. Appropriate monomer (30 kDa) and dimer (60 kDa) bands of KvAP were detected. The quantification of protein yield by TCA precipitation followed by scintillation measurement showed an increase of protein yield in the microsomal fraction from around 11 µg/mL to approximately 30 µg/mL **(d)**

3.6 High-Yield Production of Proteins Using a Continuous Exchange Cell-Free System

2d

- 43 As reported for the batch formatted cell-free reaction, all components are thawed **On ice** prior to their use in the reaction (*see* **Note 17**).
- 44 The preparation of CECF reaction is performed **On ice**.
- 45 The CHO continuous exchange cell-free reaction is performed in a two chamber device consisting of a reaction chamber (50 µL) and a feeding chamber (1000 µL). A general scheme of CHO CECF reaction is depicted in Fig. 4a. The reaction chamber contains a general cell-free reaction, the feeding chamber includes additional energy components. Both chambers are separated by a semipermeable membrane and due to diffusion gradients energy components are continuously delivered to the reaction chamber and inhibitory byproducts are removed from the reaction chamber. Thereby, protein production time is prolonged resulting in an increased protein yield. Analysis of reactor membrane cut-off by CECF synthesis of membrane protein EGFR fused to a C-terminal eYFP, results in an optimal protein yield using a membrane cut-off between 10 and 14 kDa in comparison to smaller cut-offs (3–8 kDa) (Fig. 4b) (*see* **Note 21**).
- 46 Feeding and reaction mix are prepared separately.

Table 2

List of standard reaction conditions present in a CHO CECF system

A	B	C	D
Component/Parameter	CHO CECF reaction conditions	Reaction mix	Feeding mix
Cell lysate	40% (Vol/Vol)	×	
HEPES KOH, pH 7.6	30 mM	×	×
KoAc	150 mM	×	×
Mg(OAc) ₂	3.9 mM		×
Mg(OAc) ₂	22 mM	×	
ATP	1.75 mM	×	×
CTP,GTP,UTP	0.3 mM	×	×
Amino acids	100 μM	×	×
¹⁴ C Leucine	9.9 dpm/pmol	×	×
Sodium azide	0.02%	×	
Plasmid	30 nM	×	×
T7 RNA polymerase	1 U/μL	×	
DTT	2.5 mM	×	×
Caspase inhibitor Ac-DEVD-CMK	30 μM	×	×
Temperature	30 °C	×	×
Agitation	600 RPM	×	×
Reaction time	48 h	×	×

47 The feeding mix consists of 1× translation buffer and 1× energy buffer harboring the conditions described in Table 2. Additionally, 0.02% sodium azide (*see* **Note 22**), caspase inhibitor Ac-DEVD-CMK (30 μM), ¹⁴C leucine (9.9 dpm/pmol), and ddH₂O (filling up to 1000 μL) are added to complete the feeding mixture.

48 The reaction mix is then prepared. The optimized conditions of the reaction mix differ from the standard CHO cell-free batch reaction and are illustrated in Table 2. Essential parameters which differ from the standard conditions are the concentration of Mg(OAc) (22 mM), creatine phosphate (18.5 mM), caspase inhibitor Ac-DEVD-CMK (30 μM), plasmid concentration (30 nM), and ¹⁴C leucine (9.9 dpm/pmol).

49 The reaction mixture is transferred into the dialysis device followed by the feeding mix.

50 

2d

The device is sealed with plastic foil and place into a thermomixer C for incubation at **30 °C 600 RPM** ,
48:00:00 .

51 After finishing the CECF synthesis, the sealing is removed and reaction mixture is transferred into an Eppendorf tube for further analysis.

52 Like reported for the batch based cell-free reaction, reaction mixture can be directly used for the analysis of the produced proteins. Different batches of CECF synthesized membrane protein EGFR were quantified and analyzed using

autoradiography (Fig. 4c).

- 53 The quantification was performed using **3 μ l reaction mixture** for hot TCA precipitation and further analysis by scintillation measurement. Typically, protein yields of approximately 1000 μ g/mL are obtained. An autoradiograph of EGFR shows the expected molecular weight at around 170 kDa.
- 54 Protein glycosylation can be monitored by adding 3 nM 14 C mannose to the CHO CECF reaction.
- 55 After finishing cell-free protein synthesis, acetone precipitate 14 C mannose labeled sample and can be directly applied to SDS-PAGE.
- 56 The dried gel is analyzed by autoradiography.
- 57 For the purpose of verifying the specificity of protein glycosylation, a treatment of CHO CECF sample using glycosidases PNGaseF (NEB) and EndoH (NEB) is performed according to the manufacturer's protocol. The results show the specificity of EGFR glycosylation performed in the CHO CECF system (Fig. 4d).




Fig. 4
Continuous exchange cell-free synthesis based on CHO cell lysates. **(a)** Schematic overview of the general principle of the CHO CECF reaction. The reaction vessel is divided into a reaction chamber and a feeding chamber, separated by a semipermeable membrane. The membrane protein EGFR fused to a C-terminal eYFP is used as a model protein for CHO CECF synthesis. The cut-off of the dialysis membrane is analyzed using different dialysis devices (device 1 (Scienova); device 2 (RiNA GmbH)). Fluorescence intensity of the produced EGFR-eYFP fusion protein was analyzed on μ -lidi-Slides using a multimode imager (Typhoon Trio Plus, GE Healthcare). An increase in protein fluorescence was achieved using a cut-off between 10 and 14 kDa compare to a smaller cut-off (3–8 kDa) **(b)**. For further experiments, device 2 was used. After optimizing the reaction conditions (Table 2), protein yields of approximately 1000 μ g/mL of “difficult-to-express” protein EGFR were obtained in different reaction batches **(c)**. The quantification of protein yield was performed by TCA precipitation followed by scintillation measurement. An appropriate protein band is detected on the autoradiograph, while no band is detected in the sample containing no DNA template (NTC). The glycosylation of the protein was verified by the supplementation of 14 C mannose during the CHO CECF reaction and further analysis by autoradiography **(d)**. Glyco residues were removed by EndoH and PNGaseF treatment to underline the specificity of the glycosylation band

3.7 Application of Linear Expression Templates to CHO Cell-Free Systems

58

The application of linear expression templates to a CHO cell-free system offers new possibilities for fast and easy template generation and modification. This procedure is mandatory for cloning-free high-throughput applications and the development of novel screening technologies for the production and analysis of difficult-to-express proteins.

- 59 For the application of PCR products to the CHO cell-free reactions, perform standard batch formatted as well as CECF reactions. Plasmid DNA is replaced by previously prepared linear expression template.
- 60 The productivity of batch cell-free systems based on linear expression templates are strongly dependent on the concentration of applied PCR-product. Figure 5a shows the dependency of PCR product concentration on the received protein yield in a batch formatted CHO cell-free reaction for the production of secreted protein EPO. A maximum protein yield is obtained by the application of **[M]12.5 nanogram per microliter (ng/μL) linear expression template** to the batch formatted CHO cell-free protein synthesis system.
- 61 An increase in T7 RNA polymerase concentration from 1 U/μL to **3 U/μL** results in a significant increase in protein yield in the batch system. Protein yields up to approximately 12 μg/mL of secretory EPO were obtained by a combined increase of T7 RNA polymerase and PCR product concentration (Fig. 5a) (*see Note 23*).
- 62 The application of linear DNA templates to the CHO CECF system requires an increase of T7 RNA polymerase and PCR product concentration as reported for the batch formatted system. A maximum protein yield of 350 μg/mL of membrane protein EGFR was obtained using **3 U/μL** and **[M]54 nanogram per microliter (ng/μL) linear PCR product**.




Fig. 5
Application of linear expression DNA templates to CHO cell-free protein synthesis systems. **(a)** Linear expression templates (LET) of secreted protein EPO were applied to a batch formatted CHO cell-free protein synthesis system. An increase of protein yield was detected by increasing the PCR product and T7 RNA polymerase concentrations. Protein yields up to approximately 12 μg/mL were obtained as compared to 22 μg/mL using a plasmid DNA template. **(b)** Linear expression templates of membrane protein EGFR were applied to a CHO CECF system. An influence of T7 RNA polymerase and PCR product concentrations on the productivity of the protein was detected. An increase of T7 RNA polymerase and PCR production lead to protein yields up 350 μg/mL of EGFR using a PCR product as a DNA expression template. Protein yields were derived by TCA precipitation of radio labeled proteins followed by scintillation measurement